Table 1.
Clinical Characteristics Comparison Between the TACE+ MTGs +icis Group and TACE+ MTGs Group
| Variables | TACE+MTGs+ICIs Group (n=30) | TACE+MTGs Group (n=42) | P value |
|---|---|---|---|
| Age (years) | 52.1±9.4 | 54.7±11 | 0.378 |
| Gender | 0.302 | ||
| Male | 24 (80.0) | 38 (90.5) | |
| Female | 6(20.0) | 4 (9.5) | |
| Child–Pugh classification | 0.659 | ||
| A | 7 (23.3) | 8 (19.0) | |
| B | 23 (76.7) | 34 (81.0) | |
| BCLC stage | 0.261 | ||
| B | 7 (23.3) | 15 (35.7) | |
| C | 23 (76.7) | 27 (64.3) | |
| AFP (ng/mL) | 0.561 | ||
| <400 | 18 (60) | 28 (66.7) | |
| >400 | 12 (40) | 14 (33.3) | |
| Hepatitis B | 1.000 | ||
| Yes | 28 (93.3) | 40 (95.2) | |
| No | 2 (6.7) | 2 (4.8) | |
| Liquefactive necrosis | 0.006 | ||
| Yes | 9 (30.0) | 2 (4.8) | |
| No | 21 (70.0) | 40 (95.2) | |
| Tumor size (cm) | 8.8±4.4 | 7.5±4.4 | 0.218 |
| Number of TACE | 3.9±2.4 | 3.9±1.7 | 0.114 |
| Number of cTACE | 2 (0.10) | 2 (0.9) | 0.875 |
| Number of DEB-TACE | 1.7±1.4 | 1.6±1.5 | 0.786 |
| TBIL (µmol/L) | 16.6 (8.2,45.2) | 20.9 (7.0,44.5) | 0.059 |
| AST (U/L) | 57.0 (20.0,134.0) | 54.0 (18.0,130.0) | 0.991 |
| ALT (U/L) | 51.0 (3.0,127.0) | 59.0 (4123.0) | 0.417 |
Notes: The categorical variables were reported as numbers (percentages) and all the continuous variables as means ± standard error or median (minimum, maximum), depending on variable distribution.
Abbreviations: MTGs, molecular targeted agents; ICIs, immune checkpoint inhibitors; TACE, transarterial chemoembolization; DEB-TACE, drug-eluting bead (DEB)-TACE; cTACE, conventional TACE; TBIL, total bilirubin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AFP, alpha-fetoprotein.